ArriVent BioPharma, Inc. (AVBP)

NASDAQ • Healthcare

$21

+$1.8 (+9.4%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$19

Previous Close$21

Day Range$18.18 - $21.23

Avg. Volume (3M)2.3M

Market Cap$1B

52 Week Range

$11.36$35.83

Next EarningsIn 22 daysNov 16, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$163.7M

EPS (TTM)

-$3.68

ROA (TTM)

-41.48%

Current Ratio

14.16

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-28.6%Q3 2025-$0.9

-6.4%Q4 2025-$0.83

+10.3%Q1 2026-$0.78

-9.1%Q2 2026-$0.96

-6.3%Q3 2026-$1.05

Nov 16

in 22 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -6.3%

ArriVent BioPharma trailed consensus on EPS in the second fiscal quarter of 2026, reported August 12, 2026, with preliminary results showing EPS of -$1.05 versus the -$0.99 estimate (difference -$0.06) and a GAAP net loss that widened 58.9% year over year to about -$49.9 million (from roughly -$31.4 million a year ago). The per-share loss also widened 16.7% from -$0.90 a year ago, alongside GAAP operating income of about -$52.7 million as the company continued advancing its oncology pipeline, including firmonertinib in EGFR-mutant non-small cell lung cancer. Cash use remained elevated, with operating cash flow of roughly -$39.6 million for the quarter. For the next period, consensus calls for EPS of -$1.07 on revenue of $800,000.00.

Next report — what to expect

ArriVent BioPharma, Inc. (AVBP) reports earnings on November 16, 2026. Wall Street expects EPS of -$1.06 on revenue of $800,000.00. The company has beaten EPS in 3 of its 8 most recent quarters, so traders may focus on any updates that help frame the path toward those consensus figures.

View full earnings history

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. is a NASDAQ-listed healthcare company in biotechnology that identifies, develops, and aims to commercialize medicines for cancers with unmet medical needs. In qualitative terms, it is an early-stage oncology biopharma built around a small pipeline of targeted and antibody-based drug candidates.

Name

ArriVent BioPharma, Inc.

CEO

Zhengbin Yao

Website

arrivent.com

Industry

Healthcare

Year Founded

2021

Employees

Today's Snapshot

AI-generated

AVBP closed 9.4% above yesterday's close, outperforming a weaker sector. Trading was busier than usual, with volume roughly twice its usual level. ArriVent announced that initial Phase 1 results for ARR-217, an experimental cancer drug, will be presented at ESMO.

Trading Volume

Above 10d avg 1.4M

3.2M

vs S&P 500 Today

Strong Outperformance

+9.90%

Updated: October 23, 2026 at 20:10 UTC

Technical Indicators

2 Buy3 Neutral3 Sell

AVBP shows a sell tilt driven by a defined downtrend and elevated intraday volatility, even as very short-term averages sit below the market. ADX indicates a persistent downward trend, and while the 10–20 day averages suggest short-term strength, the price remains under the 50–200 day averages, signaling longer-term resistance. ATR is relatively high and volume readings are mixed, with OBV not confirming a sustained reversal. Technical takeaway: overall sell bias—short-term lift is overshadowed by a persistent longer-term downtrend.

All signals